DIANT Pharma

About:

DIANT Pharma develops continuous processing technology for nanoparticle drug products and vaccines.

Top Investors: National Science Foundation

Description:

DIANT Pharma develops continuous processing technology for nanoparticle drug products and vaccines. They utilize a proprietary and continuous ethanol-injection system to form nanoparticles with controlled particle sizes at high flow rates, providing pharmaceutical companies with a continuous drug encapsulation technique to achieve their goals and high encapsulation processes. Founded in 2019, DIANT offers technology that is robust and reliable from R&D to manufacturing over a product’s lifespan.

Total Funding Amount:

$1.65M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Storrs Mansfield, Connecticut, United States

Founded Date:

2019-01-01

Contact Email:

sales(AT)diantpharma.com

Founders:

Antonio Costa

Number of Employees:

11-50

Last Funding Date:

2022-09-30

IPO Status:

Private

Industries: